| Field | Specification |
|---|---|
| Concentration | |
| Formulation | |
| Product Type | |
| Shipping | |
| Species | |
| Storage | |
| Target |
Overview
This GenCefe mRNA encodes CD8A, a membrane protein construct supplied for CAR T-cell engineering and targeted delivery studies. The product is formulated as lyophilised, non-encapsulated RNA and is intended for use in cell-based research applications requiring transient protein expression with reduced immunogenicity.
mRNA Construct Design
- 5′ Cap: Cap1 (m7GpppNm) — co-transcriptionally added during in vitro transcription (IVT). Cap1 includes 2′-O-methylation at the first transcribed nucleotide, closely mimicking the cap structure found on endogenous mammalian mRNA and reducing recognition by innate immune sensors (e.g., IFIT1/IFIT3).
- Modified Nucleotides: 100% N1-methylpseudouridine (m1Ψ; N1-Me-Pseudo UTP) substitution for all uridine residues. m1Ψ modification reduces TLR7/TLR8-mediated innate immune activation and PKR-driven translational suppression, resulting in improved protein expression in immunocompetent cells and primary cell types.
- Poly(A) Tail: 100–120 nt — enzymatically polyadenylated. The poly(A) tail stabilises the 3′ terminus, supports poly(A)-binding protein (PABP) recruitment, and enhances ribosome recycling for efficient cap-dependent translation.
- 5′ UTR: hHBA1 (hemoglobin subunit alpha 1 5′ UTR) — a well-characterised human UTR that supports efficient cap-dependent translation initiation.
- 3′ UTR: hHBA1 (hemoglobin subunit alpha 1 3′ UTR) — provides post-transcriptional stability and modulates mRNA decay kinetics.
- Signal Peptide: No
- Protein Tag: No
- Codon Optimisation: No (native human codon usage retained)
- mRNA Length: Provided upon order placement.
- Form: Lyophilised powder; reconstitute in DEPC-treated water as needed.
This mRNA is supplied as non-encapsulated, lyophilised powder. Delivery vehicle selection (LNP, electroporation, lipofection) is at the discretion of the end user and should be optimised for the target cell type and application.
Biological Background
Cell-surface membrane proteins are critical mediators of intercellular signalling, immune recognition, and targeted therapy development. Many represent validated or emerging therapeutic targets for antibody-based drugs, bispecific constructs, and chimeric antigen receptor (CAR) T-cell therapies. Recombinant expression via mRNA transfection delivers the native transmembrane protein in its correct topological orientation on the plasma membrane, which is essential for preserving conformational epitopes recognised by therapeutic antibodies. mRNA-based expression avoids the limitations of bacterial or insect-cell recombinant protein systems, which frequently misfold multi-pass transmembrane domains.
Research Relevance and Current Trends
- CAR T-cell target validation: mRNA transfection of target-antigen-negative cells creates antigen-positive challenge cells for functional cytotoxicity assays without stable line construction timelines.
- Bispecific antibody screening: Cell-surface mRNA expression enables high-throughput FACS-based epitope binning and competitive blocking studies for bispecific construct development.
- Conformational epitope preservation: mRNA-expressed transmembrane proteins retain native lipid-bilayer embedding, which is critical for identifying therapeutic antibodies that recognise conformation-sensitive extracellular epitopes.
Common Research Applications
- Antibody epitope mapping — mRNA-expressed surface antigens used as targets in FACS-based blocking, competing, and binding-domain characterisation studies.
- CAR T functional assays — short-term mRNA transfection of antigen-negative cell lines creates target-positive challenge cells for cytotoxicity and activation assays.
- Bispecific antibody characterisation — cell-surface antigen expression enables simultaneous dual-antigen engagement studies for bispecific constructs.
Notes for Experimental Interpretation
- Surface expression levels depend on cell type, transfection efficiency, and mRNA dose; quantify surface density by flow cytometry with a validated antibody before use in binding or killing assays.
- Complex multi-pass transmembrane proteins (e.g., GPCRs, CD3 complex subunits) may require co-expression of chaperones or partner subunits for correct folding and trafficking; confirm complex assembly with co-IP or FRET if required.
- Transient mRNA expression peaks at 24–48 h and declines; design time-sensitive assays (e.g., ADC internalisation, CAR killing) to align with the expression window for the specific target.
Synthetic mRNA products typically incorporate chemical modifications to minimize innate immune recognition. The most widely used modification is N1-methylpseudouridine (m1Ψ) substitution at all uridine positions, which reduces activation of Toll-like receptors (TLR7/TLR8) and protein kinase R (PKR), resulting in improved translational efficiency and a reduced inflammatory response. The 5′ cap structure is equally important: Cap1 (m7GpppNm), which includes 2′-O-methylation at the first transcribed nucleotide, closely mimics endogenous mammalian mRNA and limits recognition by innate immune sensors such as IFIT1 and IFIT3. Together, these modifications support more robust and sustained protein expression in research applications.
Synthetic mRNA is highly sensitive to ribonuclease (RNase) degradation and must be handled carefully. Lyophilized products should be stored at −20°C; aqueous formulations should be kept at −70°C or below. Repeated freeze-thaw cycles should be avoided — aliquoting immediately upon receipt is strongly recommended. All handling must be performed in an RNase-free environment using dedicated pipettes, nuclease-free consumables, and DEPC-treated or certified nuclease-free water. RNA integrity should be confirmed by agarose gel electrophoresis or capillary electrophoresis (e.g., Bioanalyzer or Fragment Analyzer) before use in critical experiments, particularly for transfection or in vivo delivery applications.
Linear mRNA and circular RNA (circRNA) differ fundamentally in structure, stability, and translational mechanism. Linear mRNA carries a 5′ cap and poly(A) tail that enable efficient cap-dependent translation by the ribosome; it is ideal for studies requiring rapid, high-level transient protein expression, mRNA delivery research, and immunogen modeling. circRNA lacks free 5′ and 3′ ends, making it inherently resistant to exonucleolytic degradation, which confers substantially greater intracellular stability. Translation of circRNA occurs via internal ribosome entry sites (IRES) or other cap-independent mechanisms. circRNA is particularly valuable for miRNA sponge applications, sustained transgene expression platforms, and studies of RNA stability and function. Choose linear mRNA when fast, high-yield transient expression is needed; choose circRNA when extended intracellular stability, prolonged expression, or sponge-based loss-of-function studies are the priority.
Quality-controlled synthetic mRNA should be characterized by multiple orthogonal analytical methods. Standard assessments include: agarose gel electrophoresis or capillary electrophoresis (Bioanalyzer, Fragment Analyzer) to confirm full-length transcript integrity; HPLC to assess purity and residual double-stranded RNA (dsRNA) content; UV spectrophotometry for concentration and A260/A280 ratio; and optionally LC-MS for sequence and modification verification. A Certificate of Analysis (CoA) should accompany each lot, documenting yield, purity, integrity score, and endotoxin level (LAL assay) for products used in cell-based or animal studies. Functional activity is further confirmed by in vitro transfection followed by protein detection (e.g., flow cytometry, Western blot, or luminescence assay), confirming translational competence of the final product.
Synthetic mRNA can be delivered into cells and organisms through several established modalities. For in vitro applications, lipid-based transfection reagents (lipofection), electroporation, and polymer-based nanoparticles are the most common approaches. Lipid nanoparticles (LNPs) are the gold-standard delivery system and support high transfection efficiency both in vitro and in vivo. For in vivo studies, intramuscular, intravenous, intratumoral, or intraperitoneal administration may be used depending on the target tissue and research objective; the choice of delivery vehicle (LNP, polymeric carrier, or direct injection) should be matched to the organ of interest and application. Delivery efficiency is influenced by mRNA modifications, concentration, formulation composition, and cell type; optimization experiments are recommended for each new experimental system before scaling.
Can't find the mRNA or circRNA construct you need? We offer custom synthesis and add-on services to help you move your project forward — from sequence design and codon optimization to custom mRNA synthesis and circular RNA (circRNA) production for both in vitro and in vivo applications. Options may include chemically modified mRNA (e.g., N1-methylpseudouridine substitution, Cap1 capping strategy), circRNA synthesis via chemical ligation (short segments ≤100 nt) or IVT-based cyclization (longer constructs ≥200 nt), HPLC purification, and full QC documentation including gel or Bioanalyzer integrity analysis and a Certificate of Analysis. Additional options may include multiple synthesis scales from small research batches to larger quantities, miRNA sponge circRNA constructs, IRES element selection for cap-independent circRNA translation, labels and conjugation, and delivery formulation guidance. We can also assist with negative and scramble control formats and related RNA tools when a catalog product does not meet your specifications. Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Research budgets are tight — we get it. That's why we've put together a fresh round of exclusive promotions designed to help you stock up on the reagents, kits, and consumables your lab depends on, without stretching your budget.
🔬 What's on offer right now:
10% Off Pre-Designed siRNA Sets
20% Off Transmembrane Proteins
50% Off Lab Consumables + Free Shipping
$99 Pipette Filler Promotion Package
BlasTaq 2X qPCR MasterMix - 50% OFF Limited Time Offer
DENARASE® Endonuclease — 10% Off One Order
10% OFF CELL LINES-Limited-Time Offer
